Evidence map›Paper›PMID 29882086›Full record

ArticlePsychopharmacology2018

Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes.

Aleksandra Szopa, Ewa Poleszak, Urszula Doboszewska, Mariola Herbet, Katarzyna Świąder, Elżbieta Wyska, Anna Serefko, Aleksandra Wlaź, Agnieszka Korga, Marta Ostrowska and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Aleksandra SzopaChair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland. aleksandra.szopa@umlub.pl.
Ewa PoleszakChair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Urszula DoboszewskaDepartment of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, 20-033, Lublin, Poland. urszula.doboszewska@umcs.lublin.pl.
Mariola HerbetChair and Department of Toxicology, Medical University of Lublin, Chodźki 8, 20-093, Lublin, Poland.
Katarzyna ŚwiąderChair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Elżbieta WyskaDepartment of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
Anna SerefkoChair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Aleksandra WlaźDepartment of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland.
Agnieszka KorgaChair and Department of Toxicology, Medical University of Lublin, Chodźki 8, 20-093, Lublin, Poland.
Marta OstrowskaChair and Department of Toxicology, Medical University of Lublin, Chodźki 8, 20-093, Lublin, Poland.
Piotr JuśChair and Department of Applied Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland.
Szymon JedynakChair and Department of Toxicology, Medical University of Lublin, Chodźki 8, 20-093, Lublin, Poland.
Jarosław DudkaChair and Department of Toxicology, Medical University of Lublin, Chodźki 8, 20-093, Lublin, Poland.
Piotr WlaźDepartment of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, 20-033, Lublin, Poland.
Medical University of Lublin · PLMaria Curie-Skłodowska University · PLJagiellonian University · PL

Funding

Uniwersytet Medyczny w Lublinie MNmb 18
6 · The paper itself

Abstract

rationaleDepressed patients often present increased consumption of caffeine.

objectivesWe aimed to investigate the effects of chronic treatment with caffeine (5 mg/kg, twice daily for 14 days) on the activity of single, ineffective doses of agomelatine (20 mg/kg) or mianserin (10 mg/kg) given on day 15 alone or simultaneously with caffeine.

methodsWe used the forced swim test (FST), tail suspension test (TST), and locomotor activity test in mice and quantitative real-time PCR analysis of the selected genes in the cerebral cortex (Cx).

resultsThere were no changes in the immobility time between mice that received saline and caffeine for 14 days. Administration of agomelatine or mianserin on day 15 did not produce an antidepressant-like effect, but such effect was observed after administration of agomelatine or mianserin simultaneously with caffeine on day 15, in both mice that received saline and caffeine for 14 days. In mice treated with caffeine for 14 days, joint administration of agomelatine or mianserin and caffeine on day 15 decreased solute carrier family 6, member 15 (Slc6a15), messenger RNA (mRNA) level in the Cx, compared to the group which received only the respective antidepressant on this day. Moreover, in mice treated with caffeine for 14 days, joint administration of mianserin and caffeine on day 15 decreased adenosine A1 receptor (Adora1) and catechol-O-methyltransferase (Comt) mRNA level in the Cx, compared to the group which received mianserin without caffeine on this day.

conclusionsWithdrawal of caffeine after its chronic intake can modify the activity of antidepressants. Adora1, Slc6a15, and Comt may be involved in the antidepressant-like effect observed after joint administration of caffeine and mianserin or agomelatine, following chronic treatment with caffeine.

Indexed as

AcetamidesAmino Acid Transport Systems, NeutralAnalysis of VarianceAnimalsAntidepressive AgentsAntidepressive Agents, Second-GenerationCaffeineCatechol O-MethyltransferaseCerebral CortexGene Expression RegulationHypnotics and SedativesLocomotionMaleMianserinMiceNaphthalenesAcetamidesagomelatineAmino Acid Transport Systems, NeutralAntidepressive AgentsAntidepressive Agents, Second-GenerationCaffeineCatechol O-MethyltransferaseHypnotics and SedativesMianserinNaphthalenesReceptor, Adenosine A1Slc6a15 protein, mouseAdora1AgomelatineCaffeineComtMianserinMiceSlc6a15

Identifiers

PMID29882086
PMCPMC6061707
OpenAlexW2805737886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.